Series A Round

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications. The company aims to advance innovative treatments, including a weekly-dosed oral GLP-1 drug, to address the growing global health crisis associated with obesity and related conditions. This funding will support clinical trials and the expansion of their drug pipeline. Verdiva Bio has emerged as a clinical-stage company, leveraging cutting-edge research to tackle obesity and its associated health risks. The company is strategically positioned to capitalize on the increasing demand for effective obesity treatments in a crowded market.